Summary
• Profusa, Inc. shares fell 18.2% to $0.0996 during intraday trading.
• The company announced a restructuring of Senior Secured Convertible Notes to enhance repayment flexibility and reduce dilution.
• Profusa established a partnership with Medsell in France to expand its Lumee™ technology commercialization in Europe.
Profusa, Inc. (NASDAQ: PFSA) saw its price drop to $0.0996 in intraday trading, representing a steep decline of 18.2%. The stock’s previous close was not available, but the current price reflects significant price action in the market today.
Recent Financial Restructuring Announcement
On December 30, 2025, Profusa announced a restructuring of its Senior Secured Convertible Notes. The new agreement enhances repayment flexibility and minimizes dilution by removing mandatory amortization payments. Additionally, the conversion floor price has been adjusted to $0.35, and the mandatory equity line of credit payments have increased from 33% to 50%. This restructuring is a part of the company’s efforts to recapitalize its balance sheet and support operational needs moving forward.
European Market Expansion Efforts
In a separate announcement dated December 31, 2025, Profusa revealed the establishment of a new distributor partnership with Medsell in France. This deal aims to expand the commercialization of the Lumee™ Oxygen Tissue Monitoring technology across multiple European countries. Profusa is now positioned to reach approximately 200,000 annual case incidents within the European Union, building on existing distributor relationships throughout Spain, Germany, Austria, the UK, and Scandinavia.
Market Overview and Trading Activity
As of the latest data, Profusa recorded a trading volume of approximately 27,979,120 shares, aligning closely with its 10-day average volume of 145,723,544 shares, indicating robust trading activity. In terms of technical indicators, the stock’s 20-day simple moving average stands at a -9.4% deviation, while the 50-day and 200-day averages are seeing respective divergences of -32.6% and -97.5%. Current volatility metrics display weekly volatility at 17.25% alongside a monthly figure of 16.08%.
Technical Indicators and Performance Trends
With the stock currently priced close to its year-to-date low and approximately -99.1% from its 52-week high, momentum appears to lean negative. The Relative Strength Index (RSI) is recorded at 45.45, suggesting the stock is neither overbought nor oversold under present market conditions.
Despite today’s significant price drop, the overall context of the recent announcements and the trading environment indicate a complex scenario for investors considering the outlook for Profusa amid the ongoing adjustments to its capital structure and market positioning.